241 related articles for article (PubMed ID: 24072219)
1. DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes.
Santarpia L; Iwamoto T; Di Leo A; Hayashi N; Bottai G; Stampfer M; André F; Turner NC; Symmans WF; Hortobágyi GN; Pusztai L; Bianchini G
Oncologist; 2013; 18(10):1063-73. PubMed ID: 24072219
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
5. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
7. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
9. HER-2 and topoisomerase II as predictors of response to chemotherapy.
Pritchard KI; Messersmith H; Elavathil L; Trudeau M; O'Malley F; Dhesy-Thind B
J Clin Oncol; 2008 Feb; 26(5):736-44. PubMed ID: 18258981
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
11. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer.
Zhong W; Yang Y; Zhang A; Lin W; Liang G; Ling Y; Zhong J; Yong J; Liu Z; Tian Z; Lin Q; Luo Q; Li Y; Gong C
Breast Cancer; 2020 Nov; 27(6):1147-1157. PubMed ID: 32780321
[TBL] [Abstract][Full Text] [Related]
14. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
15. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
17. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer.
Pitroda SP; Bao R; Andrade J; Weichselbaum RR; Connell PP
Clin Cancer Res; 2017 Aug; 23(15):4493-4500. PubMed ID: 28341751
[No Abstract] [Full Text] [Related]
18. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
19. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
20. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]